Estrogen-related receptor agonist

SLU-PP-332

SLU-PP-332 has been studied in mice and laboratory systems, with no human trial identified in PubMed or ClinicalTrials.gov; the app lists a half-life of 5 hours.

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

SLU-PP-332 after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.

Drawn from the half-life in the app's model, ~5 h. The model's figures

Billon and colleagues (Washington University School of Medicine and St. Louis College of Pharmacy, Saint Louis University and the Salk Institute) described SLU-PP-332 in ACS Chemical Biology in 2023, writing "we report the identification of a synthetic ERR pan agonist, SLU-PP-332, that targets all three ERRs but has the highest potency for ERRα".1 The app grades the evidence for SLU-PP-332 as emerging, and its entry describes an estrogen-related receptor gamma agonist. Billon and colleagues describe it differently, as a pan agonist that "targets all three ERRs but has the highest potency for ERRα".1 Searches on 16 November 2026 identified no controlled trial in people in PubMed or ClinicalTrials.gov, and no DailyMed drug label. In mice, the compound has been reported in work on muscle and endurance (Billon 2023), obesity models (Billon 2024), pressure-overload heart failure (Xu 2024) and the aging kidney (Wang 2023).1,2,3,4 Human-derived material in the papers read comprises cultured myoblasts from inactive women (Bonanni 2025) human kidney sections and cultured human primary proximal tubular cells (Wang 2023), and human liver S9 fractions and microsomes used for metabolism work (Möller 2026; Avliyakulov 2026); in none of these was SLU-PP-332 given to a person.5,4,6,7

The 2023 paper reports assay potencies of EC50 = 98 nM for ERRα, 230 nM for ERRβ and 430 nM for ERRγ, which fits the authors' description of highest potency for ERRα.1 The authors report that SLU-PP-332 "increases mitochondrial function and cellular respiration in a skeletal muscle cell line".1 In mice they report that "the ERRα activation was critical for enhancing exercise endurance", and that SLU-PP-332 induced expression of DDIT4, which the paper places in an acute aerobic exercise pathway, "via specific activation of ERRα".1 Xu and colleagues report in the heart that "ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection".3 They also caution that "it is not possible to determine if all potential targets or only a subset of targets were hit".3 Billon and colleagues (2024) note that "the relative balance of ERRα versus ERRγ agonist activity of a therapeutic compound may be important to avoid potential side effects".2

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5 h
Bioavailability
60%
Typical dose
10–50 mg/day
Route
Oral
Time to peak
~2 h

The second column holds the app's figures; the third holds what the papers report, none of which is a measurement in people.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the papers
Half-life~5 hNo plasma half-life for SLU-PP-332 was identified in the papers read; a microsomal stability assay on SLU-PP-332 as a reference agonist gave t1/2 = 31.3 min, which is an in vitro measure and not a plasma half-life8
Bioavailability60%No bioavailability figure for SLU-PP-332 was identified; the mouse studies gave it by intraperitoneal injection1
Time to peak~2 hIn one pharmacokinetic experiment in mice (30 mg/kg intraperitoneally, n = 3), "two hours after administration, levels of SLU-PP-332 were highest in skeletal muscle (∼0.6 μM), while levels in the plasma were lower (∼0.2 μM)"; a time to peak was not reported1
RouteOralIntraperitoneal injection in the mouse studies1,3,4

The app's figure of 5 hours sits beside its own note of an estimate of about 4 to 6 hours from preclinical data; none of the papers read gives a half-life against which to check either number. The pharmacokinetic methods in Billon 2023 are not consistent about sampling: the results text reports plasma and muscle at 2 and 6 hours, while the methods list collection at 1, 2 or 4 hours.1 The authors conclude that "SLU-PP-332 has sufficient pharmacokinetic properties to be used as an in vivo chemical tool".1 The same 2026 medicinal chemistry paper reports "extremely low kinetic solubility (0.2 μM)" for SLU-PP-332 as the reference agonist, and its authors B.E. and T.P.B. declare stock in Pelagos Pharmaceuticals, Inc.8

Metabolism in laboratory systems

Möller and colleagues (Rapid Communications in Mass Spectrometry, 2026) incubated SLU-PP-332 with human liver S9 fraction and human liver microsomes and identified nine metabolites, six Phase-I and three Phase-II conjugates.6 Avliyakulov and colleagues (UCLA Olympic Analytical Laboratory, Drug Testing and Analysis, 2026) used pooled human liver S9 fractions and report 22 metabolites, of which eight were the most abundant and "potentially useful for doping-control purposes".7 The two papers differ in how many metabolites they report (nine against 22), and Avliyakulov and colleagues write that "further studies are necessary to fully elucidate the structures of the metabolites".6,7 Möller and colleagues declare no conflicts of interest and list support from the Manfred-Donike Institute for Doping Analysis, the Ingeborg-Gross-Foundation and the Federal Chancellery of the Federal Republic of Germany.6

4

Human studies

No study giving SLU-PP-332 to people was identified in PubMed or ClinicalTrials.gov on 16 November 2026. The one entry below uses tissue from people and applies the compound to cultured cells; the pivotal in vivo work is in mice and is analyzed afterwards.

Table 4.1Human studies1 row
Study and yearDesignPeopleDose and lengthMain result
Bonanni and colleagues, Frontiers in Physiology 20255Pilot study: muscle biopsies compared between active and inactive women, plus laboratory treatment of myoblast cultures; co-funded by the Italian Ministry of University and Research20 women undergoing hip arthroplasty for coxarthrosis, 10 active and 10 inactive by self-reportSLU-PP-332 at 1 × 10−5 M for 48 h in cultured myoblasts from inactive women; the women were not given itIn cells, down-regulation of NOX4 and up-regulation of SIRT1, PGC-1α, ERRα, FNDC5, Akt and Bcl-2; no outcome in people5

Deeper analysis: Bonanni 2025 myoblast pilot study

Bonanni and colleagues (University of L'Aquila, Italy; Frontiers in Physiology, 2025) enrolled 20 women undergoing hip arthroplasty and took muscle biopsies during surgery.5 Between the groups, active women had "less functional limitation, higher handgrip strength values, and significantly reduced visual analogue scale scores", and inactive women had higher NOX4 with lower SIRT1, PGC-1α, ERRα and FNDC5 in muscle tissue.5 SLU-PP-332 was applied to myoblasts cultured from inactive women, and the authors report lower cytotoxicity and oxidative stress and more myotube formation in those cells.5 The authors write that "a limitation of our study is the small sample size, consisting of 20 elderly women", and that the division into active and inactive "is based on self-reported information regarding physical activity levels", which may carry bias.5 They conclude that "further studies are needed to clarify the molecular mechanisms involved and explore the impact of ERRs activation on muscle metabolism".5 The paper states that the authors declare no commercial or financial relationships that could be construed as a potential conflict of interest, and its funding statement names a national research ministry initiative.5

Deeper analysis: Billon 2023 muscle and endurance study in mice

Billon and colleagues reported in ACS Chemical Biology in 2023 that mice given SLU-PP-332 at 50 mg/kg twice daily intraperitoneally for 15 days at thermoneutrality had a more oxidative muscle phenotype, with n = 7 to 8 per group in the muscle analyses.1 They report that treated mice "were able to run ∼70% longer and ∼45% further than vehicle-treated mice" on a treadmill after 7 days of twice-daily injections.1 The figure legend for the running test describes an acute dose given 1 hour before running with n = 6 per group, which differs from the 7-day schedule in the text.1 In a separate 2-week study they "noted an increase in grip strength as well".1 On safety, they report "no overt toxicity" in mice given 50 mg/kg twice daily for 10 days, with normal blood counts and electrolytes and no significant change in serum creatine kinase.1 The pharmacokinetic experiment used male mice, and a search of its full text for the word "limitation" returned no match, so no limitations passage is quoted here.1 The authors list NIH grants, and three of them (T.P.B., B.E. and J.K.W.) declare that they "are stockholders in Myonid Therapeutics, Inc., which focuses on ERR based therapeutics".1

Deeper analysis: Billon 2024 obesity and metabolic syndrome study in mice

Billon and colleagues reported in the Journal of Pharmacology and Experimental Therapeutics in 2024 that SLU-PP-332 at 50 mg/kg twice daily intraperitoneally for 28 days changed energy use in chow-fed male mice (n = 8 per group) kept at thermoneutrality.2 They report that "SLU-PP-332 treatment increased fatty acid oxidation by 25% compared with vehicle-treated animals".2 Null results in those mice include "no difference in total body weight" at 28 days, and the statement that "SLU-PP-332 did not affect fed or fasted blood glucose levels".2 They add that "only relatively minor changes in plasma cholesterol and liver enzyme levels were noted".2 In diet-induced obese male mice (n = 7 per group) the treated mice "weighed ∼12% less" after 28 days, and vehicle mice gained about 5 g of fat mass against less than 0.5 g in treated mice.2 Fasting plasma glucose and insulin were lower in those mice, with no difference in fed blood glucose, and the authors note "no change in an insulin tolerance test" and "only a trend toward an increase in AKT phosphorylation" in muscle.2 In ob/ob mice (n = 8 per group) body weight showed "a trend toward a decrease", while adiposity and liver weight were significantly lower; the text gives 12 days of dosing and the figure legend gives 15 days.2 The authors acknowledge that the metabolic benefit "could not necessarily have been predicted based on conflicting data with regard to the role of ERRα"; no separate limitations section was identified.2 The paper lists NIH grants including NIAMS R01 AR069280, and states that T.P.B., J.K.W., and B.E. are stockholders in Myonid Therapeutics, Inc. and Pelagos Pharmaceuticals, Inc.2

Deeper analysis: Xu 2024 heart failure study in mice

Xu and colleagues (Circulation, 2024) designed and synthesized "2 structurally distinct pan-ERR agonists, SLU-PP-332 and SLU-PP-915" and tested them in a pressure-overload heart failure model.3 Dosing started 1 day after the transverse aortic constriction surgery, by intraperitoneal injection twice daily at 25 mg/kg throughout 6 weeks.3 The authors report that "both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival" without affecting cardiac hypertrophy.3 They also report that transverse aortic constriction induced a moderate reduction in stroke volume and cardiac output at 6 weeks, which was ameliorated by SLU-PP-915, while "332 did not show an effect in improving SV or CO".3 They also report downregulation of cell cycle and development pathways, "partially mediated by E2F1 in cardiomyocytes".3 On safety they state: "We did not observe an overt toxicity in mice dosed at 25mg/kg during the entire course of the 6-week experiment".3 The stated caveat is that "it is not possible to determine if all potential targets or only a subset of targets were hit"; the passages read give group sizes for single analyses, for example n = 5 and n = 6 to 7 for protein blots.3 Funding is NIH grants, and the paper states that "Lilei Zhang is the co-founder and consultant for Pelagos Pharmaceuticals Inc".3 The same paper states "Other authors declare no conflict of interest", while Billon 2024, which shares authors with it, states that T.P.B., J.K.W., and B.E. are stockholders in Myonid Therapeutics, Inc. and Pelagos Pharmaceuticals, Inc.3,2

Deeper analysis: Wang 2023 aging kidney study in mice

Wang and colleagues (American Journal of Pathology, 2023) gave 21-month-old mice SLU-PP-332 for 8 weeks.4 The dose was 25 mg/kg body weight per day, administered intraperitoneally, against a 3% dimethyl sulfoxide vehicle.4 The authors report that the 8-week treatment "reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines".4 They also report that ERRs "were decreased in both aging human and mouse kidneys".4 The passages read give group sizes for single analyses, for example "n = 3 to 4 each group" for electron microscopy, and no separate limitations passage was identified.4 The disclosure statement reads "None declared", and the listed grants include NIA R01 AG049493, although authors Billon, Elgendy, Walker and Burris are also authors of the Billon 2023 paper whose competing-interest statement names stock in Myonid Therapeutics.4,1

5

Doses reported in studies and on labels

No drug label giving a dose of SLU-PP-332 was identified in DailyMed on 16 November 2026, and the rows below are mouse doses (mg per kg of body weight) and one cell concentration, not doses in people. The app's typical range of 10 to 50 mg/day by mouth has no matching figure in the papers read.

Table 5.1Doses reported in studies and on labels8 rows
StudyModelDose and routeLengthGroup size
Billon 2023, pharmacokinetic experimentMale C57Bl6/J mice30 mg/kg, single intraperitoneal injectionSamples at 2 and 6 h in the results; 1, 2 or 4 h in the methodsn = 3 (results legend); n = 4 per time point (methods)1
Billon 2023, muscle histologyThree-month-old C57BL/6J mice at thermoneutrality50 mg/kg twice daily, intraperitoneal15 daysn = 7 to 8 per group1
Billon 2024, chow-fed miceMale C57Bl/6 mice at thermoneutrality50 mg/kg twice daily, intraperitoneal28 daysn = 8 per group2
Billon 2024, diet-induced obese miceMale C57BL6 mice on a high-fat diet50 mg/kg twice daily, intraperitoneal28 daysn = 7 per group2
Billon 2024, ob/ob miceThree-month-old male ob/ob mice50 mg/kg twice daily, intraperitoneal12 days in the text; 15 days in the legendn = 8 per group2
Xu 2024, pressure-overload heart failureMice after transverse aortic constriction25 mg/kg twice daily, intraperitoneal6 weeksNot stated in the passages read for the survival analysis3
Wang 2023, aging kidney21-month-old mice25 mg/kg per day, intraperitoneal8 weeksNot stated in the passages read for the albuminuria analysis4
Bonanni 2025, cultured myoblastsMyoblasts from inactive women1 × 10−5 M in culture medium48 hInactive group n = 10 women; cell assays reported as n = 25 from N = 5 experiments (cytotoxicity) and n = 9 from N = 3 experiments (viability)5
6

Side effects reported

No adverse-event report from people given SLU-PP-332 was identified in the papers read. In mice, Billon and colleagues (2023) report "no overt toxicity" at 50 mg/kg twice daily for 10 days, and Xu and colleagues report no overt toxicity at 25 mg/kg for 6 weeks.1,3 In the chow-fed mice of Billon 2024 there were "only relatively minor changes in plasma cholesterol and liver enzyme levels", and in the diet-induced obese mice there was a decrease in plasma total cholesterol, high-density lipoprotein and triglycerides with no change in low-density lipoprotein.2 These are findings in mice dosed by injection for days to weeks, and they do not describe effects in people or after oral use.

7

Bloodwork and markers

The app lists no health markers to monitor for SLU-PP-332. The mouse studies measured serum creatine kinase, plasma cholesterol fractions and liver enzymes, fed and fasted glucose, insulin and glucose tolerance tests, which are research readouts and not monitoring guidance.1,2

8

Regulatory and anti-doping status

No DailyMed label for SLU-PP-332 was identified on 16 November 2026. The WADA 2026 Prohibited List text read does not name SLU-PP-332 or an ERR agonist; searches of its text for "SLU", "exercise mimetic" and "ERR agonist" returned no match.9 The list's S0 class covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", including drugs under pre-clinical development, and prohibits such substances at all times.9 Class S4.4, metabolic modulators, lists examples of AMPK activators and PPARδ agonists.9 Avliyakulov and colleagues write that "the World Anti-Doping Agency (WADA) prohibits the use of exercise mimetics and metabolic modulators in sports", and Möller and colleagues describe SLU-PP-332 as one of the "drug candidates" being investigated as exercise mimetics.7,6 Möller and colleagues state that this "prompted the consideration of these compounds as drugs potentially relevant for sports drug testing programs".6

9

What is not known

The papers read report no in vivo half-life, oral bioavailability or time to peak for SLU-PP-332, so the app's figures of 5 hours, 60% and 2 hours have no matching source figure. No pharmacokinetic, safety or efficacy data in people were identified. The mouse work used intraperitoneal injection, and an oral route is not described in the papers read. Xu and colleagues state that their agonists "broadly hit ERR targets", yet it is unknown whether all targets or a subset were hit.3 The structures of the human in vitro metabolites are not fully elucidated, and the two metabolism papers report different numbers of metabolites.6,7

What is SLU-PP-332?

Its original authors describe it as "a synthetic ERR pan agonist" that "targets all three ERRs but has the highest potency for ERRα".1

What is the half-life of SLU-PP-332?

The app lists a half-life of 5 hours, and none of the papers read reports a plasma half-life for SLU-PP-332.8 A microsomal stability assay with SLU-PP-332 as the reference agonist gave t1/2 = 31.3 min, an in vitro measure that is not a plasma half-life.8

Is SLU-PP-332 banned by WADA?

The WADA 2026 Prohibited List text does not name SLU-PP-332.9 The List's S0 class prohibits at all times any pharmacological substance not addressed elsewhere in the List and with no current approval by a governmental regulatory health authority for human therapeutic use; the List does not state whether SLU-PP-332 falls in that class.9 Avliyakulov and colleagues write that WADA prohibits exercise mimetics and metabolic modulators.7

Is SLU-PP-332 approved as a drug?

No DailyMed label for SLU-PP-332 was identified on 16 November 2026.

Has SLU-PP-332 been tested in people?

No study giving SLU-PP-332 to people was identified in PubMed or ClinicalTrials.gov on 16 November 2026. A 2025 pilot study treated myoblasts cultured from inactive women with SLU-PP-332 at 1 × 10−5 M for 48 h; the women did not receive it.5

What did SLU-PP-332 do in mice?

In sedentary mice given 50 mg/kg twice daily intraperitoneally, Billon and colleagues report that treated mice "were able to run ∼70% longer and ∼45% further than vehicle-treated mice".1 In diet-induced obese mice, treated mice "weighed ∼12% less" after 28 days, and in chow-fed mice there was no difference in total body weight.2

Does SLU-PP-332 have a known oral bioavailability?

No oral bioavailability figure for SLU-PP-332 was identified in the papers read, and the app lists 60%.1

How is SLU-PP-332 metabolised in laboratory systems?

In human liver S9 fraction and microsomes, Möller and colleagues identified nine metabolites, and Avliyakulov and colleagues reported 22 in pooled human liver S9 fractions.6,7

What side effects have been reported for SLU-PP-332?

No adverse-event report from people was identified in the papers read. In mice, Billon and colleagues report "no overt toxicity" at 50 mg/kg twice daily for 10 days.1

12

References

  1. Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol 2023. Billon 2023
  2. Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther 2024. Billon 2024
  3. Xu W, et al. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation 2024. Xu 2024
  4. Wang XX, et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol 2023. Wang 2023
  5. Bonanni R, et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol 2025. Bonanni 2025
  6. Möller T, Krug O, Thevis M. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom 2026. Möller 2026
  7. Avliyakulov NK, Sobolevsky T, Ahrens E. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. Drug Test Anal 2026. Avliyakulov 2026
  8. Okda HE, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. Int J Biol Macromol 2026. Okda 2026
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list